It is common experience that patients with dysthyroid eye disease may present to an endocrinologist, an ophthalmologist or a neurologist. This diversity ofclinical presentation often places a differing emphasis on the purpose of medical investigations. For the endocrinologist the assessment of thyroid status is likely to be of primary concern, whereas for the ophthalmologist the diagnosis of dysthyroid eye disease itself is a more frequent problem. These two aspects of medical investigation are illustrated by the results of investigation in a series of 52 patients referred to a clinic at Moorfields where each patient is seen jointly by the author and an ophthalmologist. Following the clinical assessment thyroid status is determined by measurement of serum T3 and T4. The chief value of the thyrotrophin releasing hormone (TRH) test has been in the diagnosis of dysthyroid eye disease, though it may also assist the diagnosis of T3 thyrotoxicosis. Clinical Diagnosis ofDysthyroid Eye Disease A clinical diagnosis of dysthyroid eye disease can frequently be made with reasonable certainty. Often the association of present or previous thyroid disease in the patient or the family points immediately to the diagnosis. In those patients without such an association certain ocular findings are of particular value. Lid lag or retraction are virtually diagnostic but ptosis may also occur and in 2 of the present patients it was abolished by edrophonium chloride injection. This myasthenic component of dysthyroid eye disease heralded the onset of myasthenia gravis in one of these patients. Vertical diplopia is particularly common in dysthyroid disease and an intraocular pressure rise of more than 4mm on attempted upgaze signifies tethering of the inferior rectus muscle. The use of Rose Bengal drops may reveal superior limbic keratoconjunctivitis which does not occur with ' Present address: Wessex Neurological Centre, Southampton S09 4XY other causes of proptosis. Finally, the observation of inflammation and thickening at the insertions of extraocular muscles is of diagnostic value in those patients without proptosis. The frequency of these findings has been reported previously by Fells et al. (1975) . In the present series a clinical diagnosis of dysthyroid eye disease was made in 42 of the 52 patients. In the remaining 10 patients, the diagnosis remained in considerable doubt, and this group is considered separately.
Serum T3 and T4 Measurements
Of the 42 patients with dysthyroid eye disease 31 were judged euthyroid clinically. This impression was supported in all 31 patients by a normal serum T4 (51-154nmol/1), but the serum T3 was raised in 5 patients (normal 1.23-2.77nmol/1). It is interesting to note that within three months of these measurements 4 of the 5 had developed frank thyrotoxicosis, confirmed by a rise in serum T4 as well as T3. None of the patients with a normal serum T3 has become clinically thyrotoxic.
Only 2 patients were hypothyroid clinically and biochemically and both had been previously treated with radioiodine.
Thyrotoxicosis was diagnosed in 9 patients, a surprisingly high frequency, since all the patients were referred because of ocular complaints. In 4 of these 9 the initial complaint was of prominence of one eye, and in the remainder the complaints were of diplopia (2), visual blurring, grittiness and epiphora (1 each). None of these patients gave a spontaneous history to suggest thyrotoxicosis, but all admitted weight loss, increased sweating and irritability on questioning. The diagnosis was also apparent on examination.
In 5 of these patients the serum T4 and T3 were in the thyrotoxic range but in 4 only the serum T3 was raised, ranging from 2.92 to 6.07nmol/l. All 9 made a satisfactory response to treatment with antithyroid drugs.
TRH Tests in 42 Patients with Dysthyroid Eye Disease
Hall et al. (1970) first .reported the increase in serum thyrotrophin (TSH) following intravenous injection of normal individuals with TRH. No such increase occurs in thyrotoxic patients, presumably because of pituitary suppression by high serum T3 or T4 levels. In hypothyroid patients the TSH response to TRH is exaggerated.
The observation by Lawton et al. (1971) of an absent response to TRH in patients with Graves' disease who were nevertheless euthyroid has led to the use of TRH in the diagnosis of dysthyroid eye disease. Further investigation by Ormston et al. (1973) has shown that the TSH response to TRH may also be exaggerated in these patients, and may also be normal.
These findings have been confirmed in the 42 patients known to have dysthyroid eye disease in the present series. In the 31 euthyroid patients the TRH response was normal in 7, absent or impaired in 15 and exaggerated in 9. The TRH response was always absent in patients with a raised serum T3 regardless of whether they were clinically thyrotoxic.
TRH in the Diagnosis of Unilateral Proptosis
It might be argued that the TRH test added little to the diagnostic assessment of the 42 patients already discussed. However, the 10 remaining patients presented with unilateral proptosis, without lid retraction or other clinical evidence of dysthyroid disease. None had any relevant history, thyroid atitibodies were not detected in serum, and T3 and T4 measurements were always normal. In the absence of any evidence for the diagnosis, proptosis had been further investigated by orbital venography in 4 patients and carotid angiography in 2.
In 8 of these patients the TRH test was positive, i.e. there was no TSH response. Ormston et al. (1973) have shown a statistical correlation between T3 suppressibility and TRH responsiveness, but in an individual patient the TRH test may provide the only evidence of Graves' disease. Thus in 6 patients the T3 suppression test gave normal or equivocal results whereas the TRH test was diagnostic.
Conclusions
A diagnosis of dysthyroid eye disease can be made on clinical grounds in the majority of cases. In our experience unrecognized thyrotoxicosis is common in patients referred to an eye department and this finding confirms the importance of joint assessment of the patients. In the euthyroid patient a raised serum T3 often heralds the onset of thyrotoxicosis, as suggested by Hollander et al. (1971) , and T3 toxicosis seems particularly common in association with dysthyroid eye disease. However, the incidence may depend upon the selection of patients. Certainly measurement of serum T3, where it is available, provides more information than the serum T4 alone.
Finally, this series shows the diagnostic value of the TRH test in ophthalmological practice and it is suggested that the test should be performed early in the investigation of unilateral proptosis.
Mr Peter Fells (Moorfields Eye Hospital, City Road, London ECIV 2PD) Surgical Management of Dysthyroid Eye Disease: a Review Surgical treatment may be required with varying degrees of urgency for the widely different manifestations of dysthyroid eye disease: (1) Emergency surgery is necessary to save the integrity of the eye itself when uncontrolled corneal exposure predisposes to infection, ulceration, perforation and panophthalmitis.
(2) Equally urgent is the control of raised intraorbital pressure that causes visual loss through reduced blood supply to the optic nerve.
(3) Carefully timed surgical intervention may correct diplopia due to ocular muscle fibrosis and reduce an associated compensatory head posture. (4) Elective cosmetic surgery may be requested for marked, chronic exophthalmos and severe lid retraction.
Orbital decompression for imminent loss of vision or of the eye from high intraorbital pressure gives dramatic improvement. The preferred route for the creation of extra space for the swollen orbital contents is transantral decompression (Walsh & Ogura 1957) using the Caldwell-Luc approach through the anterior wall of the antrum and entering the orbit via the medial half of the antral roof. Further decompression into the ethmoids can be made if necessary. Most patients needing decompression have both eyes severely affected. The transantral route takes approximately 25 minutes per side by myself and less when done by an ENT surgeon. Transfrontal decompression takes the neurosurgeon 90 minutes per side and it is less acceptable to the patient.
Orbital decompression will result in worthwhile improvement in at least one and usually more of the following features: better visual acuity, restoration of visual fields, abolition of disc cedema, up to 4 mm reduction in proptosis, better lid closure and corneal healing. Ocular muscle balance is not normally altered by decompression. A slight general increase in all rotations may occur as orbital pressure and cedema are reduced, but certainly no permanent worsening of ocular movements should result. The major morbidity is of intraorbital nerve paraxsthesix which may last up to eighteen months if the nerve is severed and not
